ITRM - アイテラム・セラピュ―ティクス (Iterum Therapeutics plc) アイテラム・セラピュ―ティクス

 ITRMのチャート


 ITRMの企業情報

symbol ITRM
会社名 Iterum Therapeutics plc (アイテラム・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 Iterum Therapeutics plc is an Ireland-based clinical-stage pharmaceutical company. The Company is engaged in developing anti-infectives aimed at combatting multi-drug resistant (MDR) pathogens. The Company’s product Sulopenem is a bioavailable antibiotic covering gram-positive gram-negative and anaerobic pathogen with in-vitro activity against multidrug-resistant pathogens including Extended-Spectrum Beta-Lactamase (ESBL)-producing Escherichia (E.) coli and Klebsiella (K.) pneumoniae as well as penicillin-resistant Streptococcus (S.) pneumoniae.   アイテラム・セラピュ―ティクスはアイルランド医薬品持株会社。子会社を通じ、臨床段階で満たされていない医療ニ―ズに対応する治療法の発見・開発に従事する。多くの重症感染症の原因となる多剤耐性病原体を治療する抗感染薬を提供し、複数のバランスのとれた新薬開発に焦点を当てる。本社所在地はダブリン。   
本社所在地 Block 2 Floor 3 Harcourt Centre Harcourt Street Dublin 2 IRL
代表者氏名 Paul R. Edick ポールRエディック
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +353 1-903-8920
設立年月日 42156
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数 38人
url www.iterumtx.com
nasdaq_url https://www.nasdaq.com/symbol/itrm
adr_tso
EBITDA EBITDA(百万ドル) -45.01400
終値(lastsale) 6.6
時価総額(marketcap) 93452191.8
時価総額 時価総額(百万ドル) 89.62915
売上高 売上高(百万ドル) 0.88400
企業価値(EV) 企業価値(EV)(百万ドル) -32.33185
当期純利益 当期純利益(百万ドル) -45.18200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Iterum Therapeutics PLC revenues increased from $0K to $376K. Net loss increased from $12.1M to $27.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research_Development Expense increase from $4.4M to $12.2M (expense) Research_Development Expense increase from $2.8M to $7.7M (expense).

 ITRMのテクニカル分析


 ITRMのニュース

   Iterum Therapeutics Stock Shoots Higher As Sulopenem Application Review On Track  2021/05/28 11:04:51 Benzinga
Iterum Therapeutics plc (NASDAQ: ITRM ) has concluded a late-cycle meeting with the FDA related to its application for sulopenem etzadroxil/probenecid. Sulopenem is under review as a treatment for uncomplicated urinary tract infections in patients with a quinolone non-susceptible pathogen. The agency … Full story available on Benzinga.com
   ONVO, YEXT, CTRM and SLCA among midday movers  2021/05/28 16:39:43 Seeking Alpha
   Organovo, Iterum Therapeutics leads healthcare gainers; Provention Bio, Eton Pharmaceuticals among major losers  2021/05/28 15:03:32 Seeking Alpha
   Iterum keeps rising even as RBC analyst cautions, Premier hurt by Barclays’ double downgrade; and more in today’s analyst action  2021/05/28 12:59:51 Seeking Alpha
   FDA Panel Review Not Necessary For Iterum's Antibiotic, All Eyes On July 25  2021/05/28 04:01:03 Business Insider Markets
(RTTNews) - Iterum Therapeutics plc (ITRM) has been notified by the FDA that an Advisory Committee meeting to review the company's new drug application for Sulopenem etzadroxil/probenecid is no longer necessary. Sulopenem etzadroxil/probenecid, referred to as Oral Sulopenem, is an antibiotic therapy proposed for the treatment of uncomplicated…
   Why Iterum (ITRM) Stock Is Plunging Today?  2021/04/09 15:08:49 Benzinga
Iterum Therapeutics plc (NASDAQ: ITRM ) shares dropped after the company in an SEC filing disclosed that the FDA needs additional time to review … Full story available on Benzinga.com
   Alexander J. Denner Sells 10,000,000 Shares of Iterum Therapeutics plc (NASDAQ:ITRM) Stock  2021/02/15 09:18:41 Watchlist News
Iterum Therapeutics plc (NASDAQ:ITRM) major shareholder Alexander J. Denner sold 10,000,000 shares of the business’s stock in a transaction on Thursday, February 11th. The stock was sold at an average price of $2.59, for a total transaction of $25,900,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this […]
   92 Biggest Movers From Yesterday  2021/02/10 10:16:46 Benzinga
Gainers Applied UV, Inc. (NASDAQ: AUVI ) shares surged 280.5% to close at $19.71 on Tuesday. The company earlier announced closing on acquisition of Akida Holdings for 1.375 million shares and $901,274.96 in cash. Cloopen Group Holding Ltd. ADR (NYSE: RAAS ) gained 200% to close at $48.00 after the company priced 20 million shares at $16 per share in its upsized initial public offering (IPO) to rake $320 million in offering proceeds. KalVista Pharmaceuticals, Inc. (NASDAQ: KALV ) shares jumped 114.6% to close at $33.50 as the company announced positive topline data from a Phase 2 clinical trial demonstrating statistically and clinically significant efficacy of KVD900 as an oral on-demand treatment for hereditary angioedema attacks. Comstock Holding Companies, Inc. (NASDAQ: CHCI ) surged 98.2% to close at $8.38 after climbing over 18% on Monday. PDS Biotechnology Corporation (NASDAQ: PDSB ) gained 53.4% to close at $6.81. PDS Biotech, last week, reported preliminary efficacy achievement in Phase 2 combo trial of PDS0101 led by National Cancer Institute.
   Iterum Therapeutics plc Announces $35.0 Million Registered Direct Offering of Ordinary Shares Priced At-the-Market under Nasdaq Rules | MarketScreener  2021/02/10 04:59:01 MarketScreener
DUBLIN, Ireland and CHICAGO, Feb. 09, 2021 -- Iterum Therapeutics plc , a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat… | February 10, 2021
   Iterum Therapeutics plc Increases Previously Announced Bought Deal Public Offering of Ordinary Shares to $40.0 Million - Stocks News Feed  2021/02/04 04:34:59 Stocks News Feed
DUBLIN, Ireland and CHICAGO, Feb. 03, 2021 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (NASDAQ:ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that, due to demand, the underwriter has agreed to increase… Read More »Iterum Therapeutics plc Increases Previously Announced Bought Deal Public Offering of Ordinary Shares to $40.0 Million
   Why Iterum (ITRM) Stock Is Plunging Today?  2021/04/09 15:08:49 Benzinga
Iterum Therapeutics plc (NASDAQ: ITRM ) shares dropped after the company in an SEC filing disclosed that the FDA needs additional time to review … Full story available on Benzinga.com
   Alexander J. Denner Sells 10,000,000 Shares of Iterum Therapeutics plc (NASDAQ:ITRM) Stock  2021/02/15 09:18:41 Watchlist News
Iterum Therapeutics plc (NASDAQ:ITRM) major shareholder Alexander J. Denner sold 10,000,000 shares of the business’s stock in a transaction on Thursday, February 11th. The stock was sold at an average price of $2.59, for a total transaction of $25,900,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this […]
   92 Biggest Movers From Yesterday  2021/02/10 10:16:46 Benzinga
Gainers Applied UV, Inc. (NASDAQ: AUVI ) shares surged 280.5% to close at $19.71 on Tuesday. The company earlier announced closing on acquisition of Akida Holdings for 1.375 million shares and $901,274.96 in cash. Cloopen Group Holding Ltd. ADR (NYSE: RAAS ) gained 200% to close at $48.00 after the company priced 20 million shares at $16 per share in its upsized initial public offering (IPO) to rake $320 million in offering proceeds. KalVista Pharmaceuticals, Inc. (NASDAQ: KALV ) shares jumped 114.6% to close at $33.50 as the company announced positive topline data from a Phase 2 clinical trial demonstrating statistically and clinically significant efficacy of KVD900 as an oral on-demand treatment for hereditary angioedema attacks. Comstock Holding Companies, Inc. (NASDAQ: CHCI ) surged 98.2% to close at $8.38 after climbing over 18% on Monday. PDS Biotechnology Corporation (NASDAQ: PDSB ) gained 53.4% to close at $6.81. PDS Biotech, last week, reported preliminary efficacy achievement in Phase 2 combo trial of PDS0101 led by National Cancer Institute.
   Iterum Therapeutics plc Announces $35.0 Million Registered Direct Offering of Ordinary Shares Priced At-the-Market under Nasdaq Rules | MarketScreener  2021/02/10 04:59:01 MarketScreener
DUBLIN, Ireland and CHICAGO, Feb. 09, 2021 -- Iterum Therapeutics plc , a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat… | February 10, 2021
   Iterum Therapeutics plc Increases Previously Announced Bought Deal Public Offering of Ordinary Shares to $40.0 Million - Stocks News Feed  2021/02/04 04:34:59 Stocks News Feed
DUBLIN, Ireland and CHICAGO, Feb. 03, 2021 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (NASDAQ:ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that, due to demand, the underwriter has agreed to increase… Read More »Iterum Therapeutics plc Increases Previously Announced Bought Deal Public Offering of Ordinary Shares to $40.0 Million

 関連キーワード  (医薬品 米国株 アイテラム・セラピュ―ティクス ITRM Iterum Therapeutics plc)

 twitter  (公式ツイッターやCEOツイッターなど)